Celldex Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Celldex Therapeutics (CLDX).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$58Upside to Avg. PT+72.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$50→$57
Sep 22, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$42→$64
Sep 22, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$61→$72
Sep 10, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$46→$50
Aug 7, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$40→$46
Aug 7, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$48→$53
Jul 29, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$48→$72
Jul 22, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$54→$48
Jul 22, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$44→$40
Jul 22, 2026	Cantor Fitzgerald	Kristen Kluska	PT Cut	Overweight	$67→$61
Jul 22, 2026	Canaccord Genuity	Edward Nash	PT Cut	Buy	$62→$60
Jul 20, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$90→$100
Jun 15, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$42
Jun 10, 2026	UBS	David Dai	PT Raise	Buy	$38→$45
May 13, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$38→$54
May 8, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$45→$48
Apr 20, 2026	Barclays	Etzer Darout	Upgrade	Underweight→Overweight	$24→$45
Mar 2, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$30→$34
Feb 26, 2026	Stifel	Alex Thompson	PT Raise	Buy	$58→$68
Dec 17, 2025	Barclays	Etzer Darout	PT Raise	Underweight	$21→$24

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53

Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.

Benzinga Newsdesk

Celldex Therapeutics Inc

Celldex Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

PRO
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46

PRO
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53

People Also Watch

People Also Watch

Celldex Therapeutics Inc

Celldex Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

PROHC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

PROCantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

PROMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

PROMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46

PROBarclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

PRO
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46

PRO
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53